Lung cancer is the top cause of cancer deaths globally.Advances in immune checkpoint inhibitors(ICIs)have transformed cancer treatment,but their use in lung cancer has led to more side effects.This study examined if p...Lung cancer is the top cause of cancer deaths globally.Advances in immune checkpoint inhibitors(ICIs)have transformed cancer treatment,but their use in lung cancer has led to more side effects.This study examined if past pulmonary tuberculosis(TB)affects ICIs’effectiveness and safety in lung cancer treatment.We reviewed lung cancer patients treated with ICIs at Beijing Chest Hospital from January 2019 to August 2022.展开更多
脑转移瘤是成人恶性神经系统肿瘤最常见的病因。针对这一部分人群,治疗手段有限,预后不佳。近年来,以程序性死亡受体1(programmed cell death protein 1,PD-1)及程序性死亡受体配体1(programmed cell death protein ligand 1,PD-L1)抑...脑转移瘤是成人恶性神经系统肿瘤最常见的病因。针对这一部分人群,治疗手段有限,预后不佳。近年来,以程序性死亡受体1(programmed cell death protein 1,PD-1)及程序性死亡受体配体1(programmed cell death protein ligand 1,PD-L1)抑制剂为主的免疫治疗,给恶性肿瘤的治疗模式带来了革新。免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)彻底改变了晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗模式。ICI在某些驱动基因阴性的NSCLC脑转移瘤治疗中,取得了令人鼓舞的结果。然而,针对脑转移瘤患者的临床研究,不仅相应的临床数据有限,其疗效的评价也缺乏统一标准。本文旨在阐述不同的疗效评价标准及其在临床研究中的应用,比较之间的异同,并对未来发展趋势进行展望。展开更多
基金supported by the Beijing Hospitals Authority Clinical Medicine Development of Special Funding(ZYLX202122)Beijing Key Clinical Specialty Project(20201214)+1 种基金Tongzhou Lianggao Talents Project(No.YHLJ202005)Beijing Nova Program(20220484169&20230484295).
文摘Lung cancer is the top cause of cancer deaths globally.Advances in immune checkpoint inhibitors(ICIs)have transformed cancer treatment,but their use in lung cancer has led to more side effects.This study examined if past pulmonary tuberculosis(TB)affects ICIs’effectiveness and safety in lung cancer treatment.We reviewed lung cancer patients treated with ICIs at Beijing Chest Hospital from January 2019 to August 2022.
文摘脑转移瘤是成人恶性神经系统肿瘤最常见的病因。针对这一部分人群,治疗手段有限,预后不佳。近年来,以程序性死亡受体1(programmed cell death protein 1,PD-1)及程序性死亡受体配体1(programmed cell death protein ligand 1,PD-L1)抑制剂为主的免疫治疗,给恶性肿瘤的治疗模式带来了革新。免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)彻底改变了晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗模式。ICI在某些驱动基因阴性的NSCLC脑转移瘤治疗中,取得了令人鼓舞的结果。然而,针对脑转移瘤患者的临床研究,不仅相应的临床数据有限,其疗效的评价也缺乏统一标准。本文旨在阐述不同的疗效评价标准及其在临床研究中的应用,比较之间的异同,并对未来发展趋势进行展望。
